Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Maria Geretti

Showing results (151-160 of 175) with videos related to

Pageof 18
Sort By:
JAMA|April 7, 2011
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysisJonathan Z Li, Roger Paredes, Heather J Ribaudo, et al.
The Journal of Infectious Diseases|April 10, 2004
A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipientsFrank M Mattes, Emma G Hainsworth, Anna-Maria Geretti, et al.
Antiviral Therapy|June 20, 2017
The association between detected drug resistance mutations and CD4<sup>+</sup> T-cell decline in HIV-positive individuals maintained on a failing treatment regimenAnna Schultze, Roger Paredes, Caroline Sabin, et al.
Plos One|April 25, 2013
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy responseJurgen Vercauteren, Gertjan Beheydt, Mattia Prosperi, et al.
AIDS (London, England)|March 15, 2005
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practiceAndrew N Phillips, David Dunn, Caroline Sabin, et al.
The Journal of Antimicrobial Chemotherapy|January 4, 2011
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatmentLinos Vandekerckhove, Chris Verhofstede, Els Demecheleer, et al.
The Lancet. Global Health|October 18, 2025
Causes, associated exposures, and outcomes of cirrhosis and hepatocellular carcinoma in Malawi: an observational cohort and case-control studyAlexander J Stockdale, Benno Kreuels, Isaac T Shawa, et al.
The Journal of Infectious Diseases|November 9, 2021
Hepatitis B Vaccination Impact and the Unmet Need for Antiviral Treatment in Blantyre, MalawiAlexander J Stockdale, James E Meiring, Isaac T Shawa, et al.
HIV Medicine|March 4, 2014
British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013Ed Wilkins, Mark Nelson, Kosh Agarwal, et al.
The Lancet. Infectious Diseases|August 30, 2018
Incidence, aetiology, and sequelae of viral meningitis in UK adults: a multicentre prospective observational cohort studyFiona McGill, Michael J Griffiths, Laura J Bonnett, et al.
Pageof 18

Showing results (151-160 of 175) with videos related to

Sort By:
Pageof 18
JAMA|April 7, 2011
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysisJonathan Z Li, Roger Paredes, Heather J Ribaudo, et al.
The Journal of Infectious Diseases|April 10, 2004
A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipientsFrank M Mattes, Emma G Hainsworth, Anna-Maria Geretti, et al.
Antiviral Therapy|June 20, 2017
The association between detected drug resistance mutations and CD4<sup>+</sup> T-cell decline in HIV-positive individuals maintained on a failing treatment regimenAnna Schultze, Roger Paredes, Caroline Sabin, et al.
Plos One|April 25, 2013
Clinical evaluation of Rega 8: an updated genotypic interpretation system that significantly predicts HIV-therapy responseJurgen Vercauteren, Gertjan Beheydt, Mattia Prosperi, et al.
AIDS (London, England)|March 15, 2005
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practiceAndrew N Phillips, David Dunn, Caroline Sabin, et al.
The Journal of Antimicrobial Chemotherapy|January 4, 2011
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatmentLinos Vandekerckhove, Chris Verhofstede, Els Demecheleer, et al.
The Lancet. Global Health|October 18, 2025
Causes, associated exposures, and outcomes of cirrhosis and hepatocellular carcinoma in Malawi: an observational cohort and case-control studyAlexander J Stockdale, Benno Kreuels, Isaac T Shawa, et al.
The Journal of Infectious Diseases|November 9, 2021
Hepatitis B Vaccination Impact and the Unmet Need for Antiviral Treatment in Blantyre, MalawiAlexander J Stockdale, James E Meiring, Isaac T Shawa, et al.
HIV Medicine|March 4, 2014
British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013Ed Wilkins, Mark Nelson, Kosh Agarwal, et al.
The Lancet. Infectious Diseases|August 30, 2018
Incidence, aetiology, and sequelae of viral meningitis in UK adults: a multicentre prospective observational cohort studyFiona McGill, Michael J Griffiths, Laura J Bonnett, et al.
Pageof 18